Doxercalciferol

Names

[ Name ]:
Doxercalciferol

[Synonym ]:
1,3-Cyclohexanediol, 4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(1R,2E,4R)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-, (1R,3S,5Z)-
UNII-3DIZ9LF5Y9
(1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol
doxercalciferol
MFCD01076571
(1R,3S,5Z)-4-methylidene-5-[(2E)-2-{(1R,3aS,7aR)-7a-methyl-1-[(1R,2E,4R)-1,4,5-trimethylhex-2-en-1-yl]octahydro-4H-inden-4-ylidene}ethylidene]cyclohexane-1,3-diol
Hectorol
1,3-Cyclohexanediol, 4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-, (1R,3S,5Z)-
9,10-secoergosta-5,7,10,22-tetraene-1,3-diol, (1S,3R,5Z,7E,22E)-

Biological Activity

[Description]:

Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevent renal disease.

[Related Catalog]:

Signaling Pathways >> Vitamin D Related >> VD/VDR

Research Areas >> Metabolic Disease

[Target]

Vitamin D receptor[1]

[In Vivo]

Doxercalciferol (0.083, 0.167 or 0.333 μg/kg, i.p.) elevates serum phosphorus at Week 6 in 5/6 nephrectomized (NX) rats. Doxercalciferol (0.167 and 0.333 μg/kg) also increases serum calcium and Ca × P at Weeks 2 and 6, and enhances increased pulse wave velocity (PWV) at Week 6 in 5/6 nephrectomized (NX) rats. Doxercalciferol blocks PTH from rising at 0.083 μg/kg, and lowers serum PTH to the SHAM level[1]. Doxercalciferol (125 ng/kg, i.p. thrice per week) increases expression of VDR mRNA level and renal expression of TRPV5 in NON mice fed a HF diet. Doxercalciferol also improves proteinuria, prevents loss of podocytes, and accumulation of extracellular matrix proteins in HF diet-induced mice. Doxercalciferol inhibits the expression of profibrotic growth factors (TGF-β, PAI-1, and connective tissue growth factor (CTGF)), and blocks increased expression of the renin-angiotensin-aldosterone system in mice fed a HF diet. Furthermore, Doxercalciferol suppresses macrophage infiltration, decreases NF-κb activity, and preventes expression of proinflammatory cytokine and the increase in renal lipid accumulation in mice fed a HF diet[2]. Doxercalciferol (30 ng/kg, i.p. thrice per week) prevents albuminuria, markedly attenuates podocyte loss and apoptosis, and reduces glomerular fibrosis in streptozotocin-induced diabetic mice[3].

[Animal admin]

Rats[1] Male, Sprague-Dawley, 5/6 nephrectomized (NX) rats (∼200 gm) are used 1 week after nephrectomy. The nephrectomy is performed using a standard two-step surgical ablation procedure. Beginning 2 weeks post-nephrectomy, rats are maintained on a high phosphorus diet (0.9% phosphorus and 0.6% calcium) for the duration of the study to induce secondary hyperparathyroidism. On Day 0, SHAM and 5/6 NX rats (n = 7-10 per group) receive vehicle (5% EtOH/95% propylene glycol; 0.4 mL/kg; i.p.) or VDRA (paricalcitol or Doxercalciferol; 0.083, 0.167 or 0.333 μg/kg; intraperitoneally) three times per week for 41 days (n = 6-10 per group). These doses are chosen based on the fact that lower doses (0.021 and 0.042 μg/kg; i.p.) of either compound are not PTH suppressive after 2 or 6 weeks of treatment in this model of CKD. On Days 0, 13 and 41, blood is collected (24 h post-dose). On Days 0, 13 and 41 (24 h post-dose), animals are anaesthetized with ketamine (50 mg/kg) and blood is collected via the tail vein for PTH and serum blood chemistry determinations[1].

[References]

[1]. Noonan W, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant. 2008 Dec;23(12):3824-30.

[2]. Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011 Mar;300(3):F801-10.

[3]. Wang Y, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.0±0.1 g/cm3

[ Boiling Point ]:
538.7±50.0 °C at 760 mmHg

[ Melting Point ]:
138-140ºC

[ Molecular Formula ]:
C₂₈H₄₄O₂

[ Molecular Weight ]:
412.648

[ Flash Point ]:
224.0±24.7 °C

[ Exact Mass ]:
412.334137

[ PSA ]:
40.46000

[ LogP ]:
8.15

[ Vapour Pressure ]:
0.0±3.3 mmHg at 25°C

[ Index of Refraction ]:
1.541

[ Storage condition ]:
Desiccate at -20°C

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: VS2950000

CHEMICAL NAME :: 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-

CAS REGISTRY NUMBER :: 54573-75-0

LAST UPDATED :: 199612

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C28-H44-O2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3500 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04- Volume(issue)/page/year: 178,432,1985 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 560 ug/kg/4W-I

TOXIC EFFECTS :: Nutritional and Gross Metabolic - changes in calcium Related to Chronic Data - death

REFERENCE :: PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04- Volume(issue)/page/year: 178,432,1985

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H300

[ Precautionary Statements ]:
P264-P301 + P310

[ Hazard Codes ]:
T+

[ Risk Phrases ]:
28

[ Safety Phrases ]:
28-36/37-45

[ RIDADR ]:
UN 2811 6.1 / PGIII

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

Calcium regulates FGF-23 expression in bone.

Endocrinology 154(12) , 4469-82, (2013)

Calcium has recently been shown to regulate fibroblast growth factor 23 (FGF-23), a bone-derived phosphate and vitamin D-regulating hormone. To better understand the regulation of FGF-23 by calcium, p...

Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Clin. J. Am. Soc. Nephrol. 10(1) , 98-109, (2015)

Elevated parathyroid hormone levels may be associated with adverse clinical outcomes in patients on dialysis. After the introduction of practice guidelines suggesting higher parathyroid hormone target...

A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.

Molecules 14(10) , 3869-80, (2009)

Alfacalcidol (1alpha-hydroxyvitamin D(3)) has been widely used since 1981 as a prodrug for calcitriol (1alpha,25-dihydroxyvitamin D(3)) in the treatment of hypocalcemia, chronic renal failure, hypopar...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.